Literature DB >> 25002612

SPSB1 may have MET its match during breast cancer recurrence.

Yuanbo Qin1, Sandra S McAllister2.   

Abstract

SUMMARY: Disease recurrence is the most common cause of death for patients with breast cancer, yet little is known about the molecular mechanisms underlying this process. Using inducible transgenic mouse model systems, Feng and colleagues identified SPSB1 as a determinant of breast cancer recurrence by virtue of its ability to protect tumor cells from apoptosis through c-MET activation. ©2014 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25002612      PMCID： PMC4090600          DOI： 10.1158/2159-8290.CD-14-0505

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  10 in total

1.  The SPRY domain-containing SOCS box protein 1 (SSB-1) interacts with MET and enhances the hepatocyte growth factor-induced Erk-Elk-1-serum response element pathway.

Authors:  Dakun Wang; Zaibo Li; Edward M Messing; Guan Wu
Journal:  J Biol Chem       Date:  2005-02-15       Impact factor: 5.157

2.  SPSB1 promotes breast cancer recurrence by potentiating c-MET signaling.

Authors:  Yi Feng; Tien-Chi Pan; Dhruv K Pant; Kristi R Chakrabarti; James V Alvarez; Jason R Ruth; Lewis A Chodosh
Journal:  Cancer Discov       Date:  2014-04-30       Impact factor: 39.397

Review 3.  MET signalling: principles and functions in development, organ regeneration and cancer.

Authors:  Livio Trusolino; Andrea Bertotti; Paolo M Comoglio
Journal:  Nat Rev Mol Cell Biol       Date:  2010-12       Impact factor: 94.444

4.  A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology.

Authors:  Edward J Gunther; George K Belka; Gerald B W Wertheim; James Wang; Jennifer L Hartman; Robert B Boxer; Lewis A Chodosh
Journal:  FASEB J       Date:  2002-03       Impact factor: 5.191

5.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Authors:  Alexa B Turke; Kreshnik Zejnullahu; Yi-Long Wu; Youngchul Song; Dora Dias-Santagata; Eugene Lifshits; Luca Toschi; Andrew Rogers; Tony Mok; Lecia Sequist; Neal I Lindeman; Carly Murphy; Sara Akhavanfard; Beow Y Yeap; Yun Xiao; Marzia Capelletti; A John Iafrate; Charles Lee; James G Christensen; Jeffrey A Engelman; Pasi A Jänne
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

6.  The SPRY domain-containing SOCS box protein SPSB2 targets iNOS for proteasomal degradation.

Authors:  Zhihe Kuang; Rowena S Lewis; Joan M Curtis; Yifan Zhan; Bernadette M Saunders; Jeffrey J Babon; Tatiana B Kolesnik; Andrew Low; Seth L Masters; Tracy A Willson; Lukasz Kedzierski; Shenggen Yao; Emanuela Handman; Raymond S Norton; Sandra E Nicholson
Journal:  J Cell Biol       Date:  2010-07-05       Impact factor: 10.539

7.  Par-4 downregulation promotes breast cancer recurrence by preventing multinucleation following targeted therapy.

Authors:  James V Alvarez; Tien-Chi Pan; Jason Ruth; Yi Feng; Alice Zhou; Dhruv Pant; Joshua S Grimley; Thomas J Wandless; Angela Demichele; Lewis A Chodosh
Journal:  Cancer Cell       Date:  2013-06-13       Impact factor: 31.743

8.  Structural basis for Par-4 recognition by the SPRY domain- and SOCS box-containing proteins SPSB1, SPSB2, and SPSB4.

Authors:  Panagis Filippakopoulos; Andrew Low; Timothy D Sharpe; Jonas Uppenberg; Shenggen Yao; Zhihe Kuang; Pavel Savitsky; Rowena S Lewis; Sandra E Nicholson; Raymond S Norton; Alex N Bullock
Journal:  J Mol Biol       Date:  2010-06-16       Impact factor: 5.469

9.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.

Authors:  Ravid Straussman; Teppei Morikawa; Kevin Shee; Michal Barzily-Rokni; Zhi Rong Qian; Jinyan Du; Ashli Davis; Margaret M Mongare; Joshua Gould; Dennie T Frederick; Zachary A Cooper; Paul B Chapman; David B Solit; Antoni Ribas; Roger S Lo; Keith T Flaherty; Shuji Ogino; Jennifer A Wargo; Todd R Golub
Journal:  Nature       Date:  2012-07-26       Impact factor: 49.962

10.  C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?

Authors:  Colan M Ho-Yen; Andrew R Green; Emad A Rakha; Adam R Brentnall; Ian O Ellis; Stephanie Kermorgant; J L Jones
Journal:  Cancer       Date:  2013-10-21       Impact factor: 6.860
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.